Literature DB >> 16046590

Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.

C Meyer1, B P McGrath, H J Teede.   

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is associated with insulin resistance (IR) and the metabolic syndrome. There are no adequate data demonstrating significantly increased cardiovascular disease (CVD) mortality. In the absence of clinical outcome studies, surrogate markers of early CVD can provide insight into early CVD.
OBJECTIVE: The aim of this study was to clarify whether overweight women with PCOS have an increased prevalence of cardiovascular risk factors and early CVD, compared with age- and body mass index-matched controls, to determine the contribution of PCOS per se to CVD status. DESIGN AND PATIENTS: This was a case control study of 100 overweight women with PCOS and 20 subjects of similar body mass index and age. MAIN OUTCOME MEASURES: Noninvasive markers of early CVD [carotid intimal media thickness, pulse wave velocity (PWV), and brachial arterial flow-mediated vasodilation] were measured. Metabolic parameters studied included insulin, glucose, C-reactive protein, lipids, and androgens.
RESULTS: Subjects with PCOS had elevated testosterone (2.5 +/- 0.2 vs. 1.3 +/- 0.1 nmol/liter), dehydroepiandrosterone sulfate (4.9 +/- 0.3 vs. 3.6 +/- 0.4 mmol/liter), fasting insulin (19.6 +/- 1.4 vs. 6.8 +/- 0.8 microU/ml), and homeostasis model assessment of IR (4.1 +/- 0.3 vs. 1.3 +/- 0.2), compared with controls. In addition, those with PCOS had elevated cholesterol (5.1 +/- 0.1 vs. 4.6 +/- 0.2 mmol/liter) and triglycerides (1.4 +/- 0.1 vs. 0.9 +/- 0.1 mmol/liter), whereas there were no differences in either C-reactive protein or 24-h ambulatory blood pressure parameters. Subjects with PCOS also had increased arterial stiffness (PWV, 7.4 +/- 0.1 vs. 6.6 +/- 0.2 m/sec) and endothelial dysfunction (flow-mediated vasodilation, 9.8 +/- 0.4 vs. 13.3 +/- 0.9), compared with controls. There was no difference in mean intimal media thickness between the groups. Stepwise regression in PCOS subjects showed that IR and lipids were independent predictors of PWV.
CONCLUSION: Overweight women with PCOS have increased cardiovascular risk factors and evidence of early CVD, compared with weight-matched controls, potentially related to IR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046590     DOI: 10.1210/jc.2005-0011

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  50 in total

1.  Genetic variations in SREBP-1 and LXRα are not directly associated to PCOS but contribute to the physiological specifics of the syndrome.

Authors:  Birgit Knebel; Onno E Janssen; Susanne Hahn; Sylvia Jacob; Ulrike Nitzgen; Jutta Haas; Dirk Muller-Wieland; Jorg Kotzka
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

2.  The Impact of Bariatric Surgery Compared to Metformin Therapy on Pregnancy Outcomes in Patients with Polycystic Ovarian Syndrome: a Systematic Review and Meta-analysis.

Authors:  Catherine Chang; Steven Chang; Jillian Poles; Violeta Popov
Journal:  J Gastrointest Surg       Date:  2021-01-22       Impact factor: 3.452

Review 3.  Identification and treatment of metabolic complications in pediatric obesity.

Authors:  Katie Larson Ode; Brigitte I Frohnert; Brandon M Nathan
Journal:  Rev Endocr Metab Disord       Date:  2009-09       Impact factor: 6.514

Review 4.  The Role of Physical Activity in Preconception, Pregnancy and Postpartum Health.

Authors:  Cheryce L Harrison; Wendy J Brown; Melanie Hayman; Lisa J Moran; Leanne M Redman
Journal:  Semin Reprod Med       Date:  2016-05-11       Impact factor: 1.303

5.  Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome.

Authors:  Ekwutosi M Okoroh; Sheree L Boulet; Mary G George; W Craig Hooper
Journal:  Thromb Res       Date:  2015-10-17       Impact factor: 3.944

6.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

7.  Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.

Authors:  Sonali S Patel; Uyen Truong; Martina King; Annie Ferland; Kerrie L Moreau; Jennifer Dorosz; John E Hokanson; Hong Wang; Gregory L Kinney; David M Maahs; Robert H Eckel; Kristen J Nadeau; Melanie Cree-Green
Journal:  Vasc Med       Date:  2017-01-17       Impact factor: 3.239

8.  Effect of exercise training on insulin sensitivity, mitochondria and computed tomography muscle attenuation in overweight women with and without polycystic ovary syndrome.

Authors:  S K Hutchison; H J Teede; D Rachoń; C L Harrison; B J Strauss; N K Stepto
Journal:  Diabetologia       Date:  2012-01-13       Impact factor: 10.122

9.  Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.

Authors:  L J Moran; C Meyer; S K Hutchison; S Zoungas; H J Teede
Journal:  J Endocrinol Invest       Date:  2009-10-15       Impact factor: 4.256

10.  Anteroposterior diameter of the infrarenal abdominal aorta is higher in women with polycystic ovary syndrome.

Authors:  Marco Matteo Ciccone; Stefano Favale; Anish Bhuva; Pietro Scicchitano; Vito Caragnano; Cristina Lavopa; Giovanni De Pergola; Giuseppe Loverro
Journal:  Vasc Health Risk Manag       Date:  2009-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.